A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Recruiting
Observational Study
Graft-Versus-Host Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 0 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 395 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with acute and chronic GVHD
* Patients treated with ruxolitinib
Exclusion Criteria:
None
Other protocol-defined inclusion/exclusion criteria may apply.
Contacts
Novartis Pharmaceuticals
CONTACT